lobbying_activities: 2149476

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2149476	84d3cf1b-7bd4-474f-841b-acc48288b066	Q2	LUPIN PHARMACEUTICALS INC	401104766	LUPIN PHARMACEUTICALS INC	2018	second_quarter	CPT	CREATES Act (S.974/H.R.2212) - addresses REMS and market entry issues. PACED Act (S.2514) - restores power to PTO to review patents regardless of sovereign immunity claims CARA 2.0 (S.2456/H.R.5311) - addresses opioid abuse crisis	HOUSE OF REPRESENTATIVES,SENATE		99267	0	0	2018-07-18T10:57:17.273000-04:00